Marco's Morning Report — Thursday, August 6, 2026

Morning, Marco. Big night for the vaccine file — FDA licensed the first mRNA flu shot late yesterday, and the coverage story behind it is messier than the approval story. Meanwhile CDC's cyclospora page finally caught up with what the states have been reporting, and the number is a lot bigger than the one you've been carrying around. Coffee first, then Section A.

A · Top Stories

New

FDA approves mFlusiva — the first mRNA seasonal flu vaccine — for adults 50 and older

The agency signed off Wednesday evening on Moderna's mRNA-1010, marketed as mFlusiva. Two different approvals in one label: standard approval for ages 50–64, based on a 40,805-participant Phase 3 trial across 11 countries showing a 27% relative reduction in RT-PCR-confirmed influenza versus a standard-dose comparator; and accelerated approval for 65 and older, based on immunogenicity in a 2,992-patient trial, with clinical benefit to be confirmed in a post-marketing study against high-dose or adjuvanted vaccine. Side effects were more frequent in the mRNA arm — mostly mild, one to two days. Moderna expects supply for the 2026–27 season.

Why it matters to you: the practical bottleneck isn't the label, it's ACIP. The reconstituted committee's votes since June 2025 were nullified and appointments stayed by a federal district court in Massachusetts, so there is currently no mechanism to issue a recommendation for mFlusiva — and both Medicare and commercial plans key coverage off ACIP. You could have an FDA-approved flu vaccine this fall that your discharge order set can't get paid for on a 78-year-old.

Action: ask pharmacy and P&T now, before September, whether mFlusiva goes on formulary and what the discharge flu-vaccine order does with a licensed product carrying no ACIP recommendation. Better to have that answer in August than at 3 a.m. in October. STAT · Moderna release · coverage problem

Update

Cyclospora: CDC's national count jumps to 10,468 confirmed across 47 states, 517 hospitalizations, 2 deaths

The surveillance page was rebuilt Tuesday and the gap between the federal number and what states were reporting has closed hard. Through August 3: 10,468 laboratory-confirmed domestic cases in 47 states, 517 hospitalizations, 2 deaths. CDC is separately aware of more than 12,255 additional cases that aren't lab-confirmed or need travel exposure ruled out — many of them still coming from Michigan. Median age 45, range 1 to 98; median onset July 4. An additional 1,341 travel-associated cases sit on top of that. CDC estimates a six-week lag between onset and reporting, so this number is still climbing on cases that already happened.

Why it matters to you: 47 states means the geographic screen is gone — "did you travel?" no longer narrows anything. The clinical picture that lands on your service is the frail elderly admit with two weeks of watery diarrhea, weight loss, and an AKI on top of a diuretic and an ACE inhibitor. Treatment remains TMP-SMX 7–10 days for immunocompetent adults; consider longer courses in the immunocompromised.

Action: keep Cyclospora on the differential for any summer diarrheal illness lasting more than three days, and remember it won't show up on a standard O&P — it needs the specific request. CDC surveillance · HAN 531

Update

Salmonella Javiana source confirmed: jalapeños from Sinaloa, recall agreed, restaurant risk closed

CDC published its outbreak page Wednesday: 345 cases, 36 hospitalizations, 0 deaths, 27 states. Epidemiologic and traceback data point to jalapeño peppers grown in Sinaloa, Mexico and distributed by Coast Citrus Distributors, which has agreed to recall. Of 191 people interviewed, 177 (93%) had eaten at a Mexican-style fast-casual restaurant; meal dates ran June 14 to July 14. Chipotle changed suppliers nationwide on July 20 and QDOBA pulled jalapeños entirely July 28, so CDC and FDA say there's no current ongoing risk from those chains. FDA is still checking whether any product reached grocery stores.

Why it matters to you: the exposure window is now closed and dated, which changes the history you take. A patient with Salmonella-pattern illness and a Chipotle meal in late July is almost certainly unrelated; one with an early-July meal fits. Same drill as always for the 65+ crowd — this is the group that gets bacteremic.

Action: narrow the restaurant question to the June 14–July 14 window for jalapeños. The lettuce question stays open-ended — that outbreak is not closed. CDC · FDA advisory

B · The Debate

Should adults 65 and older be offered the new mRNA flu vaccine this season?

Why it's live right now: FDA licensed mFlusiva on Wednesday with a split label — full approval for 50–64, accelerated approval for 65+ resting on immune response rather than demonstrated clinical benefit. That's the same population, and the same evidentiary question, that produced a rare refusal-to-file letter from the agency six months ago and then a reversal a week later.

The case for

FDA's Vaccines and Related Biological Products Advisory Committee — nine physicians and vaccine scientists, unanimous

The benefit-risk balance is favorable and the data are not thin: 40,805 participants across 11 countries, a 27% relative reduction in confirmed influenza against a standard-dose comparator in the 50–64 group, and a safety profile with no new signals — more reactogenicity, but mild and short-lived. Withholding a licensed vaccine from the age band that carries nearly all of the flu mortality, on the grounds that the comparator wasn't the one American guidelines prefer, protects a methodological point at the cost of a real one.

There's also an argument that has nothing to do with this season. mRNA manufacturing collapses the lead time that forces WHO strain selection months ahead of circulation, which is a recurring source of mismatch; and a licensed seasonal mRNA flu vaccine materially shortens the regulatory path to a pandemic flu vaccine if one is ever needed. VRBPAC vote, June 18

The case against

Vinay Prasad, then FDA head of biologics — February 2026 refusal-to-file letter

The trial answers a question no American clinician is asking. Adults 65 and older in the United States are preferentially recommended high-dose or adjuvanted flu vaccine, and Moderna compared its product to neither — it used standard dose. A 27% edge over standard dose tells you nothing about whether mFlusiva beats what your patient would otherwise be getting, and the letter noted the agency had raised the comparator issue with the company before the trial began.

The 65+ indication now rests on immunogenicity, with clinical benefit deferred to a post-marketing trial — accelerated approval logic imported into vaccines, where the population is healthy and enormous and the alternative is not nothing but an already-effective product. Prasad's position was overturned within a week and he left the agency in April; the evidentiary gap he named is unchanged. STAT, Feb 10

Where it might land: two decision points — Moderna's committed Phase 4 head-to-head against high-dose/adjuvanted vaccine, and whether ACIP is reconstituted in time to vote before the 2026–27 season, which is what actually determines whether a 70-year-old can get the shot paid for.

C · On My Radar

Hospitalists and AI, quantified. SHM's 2026 Workforce Experience Report finds 64% of hospitalists now using AI and 73% of those reporting benefit — but only about a third say they've had adequate training. Top uses: decision support, chart summarization, coding, ambient listening. SHM

Puerto Rico goes to hard rationing. More than 180,000 customers in San Juan, Carolina, Juncos, Gurabo, Trujillo Alto, Canóvanas and Loíza go on 48-hours-on/48-hours-off water service starting Friday. July was San Juan's driest month in over 120 years; ~25% of the island is in severe drought, another 36% moderate. Gov. González won't put a date on when rationing ends. Al Jazeera

Cuba's grid back up after the sixth national collapse of 2026. Restored 11:35 a.m. Monday with Unit 8 at Máximo Gómez, after storms disrupted the first restoration attempt. Generation deficits persist; fuel supply hasn't recovered since the Venezuelan source was cut. CNN

Iran / Hormuz talks described as close. Oman-mediated negotiations on safe inbound and outbound shipping lanes assessed positively at both technical and political levels; Bessent said an agreement could come "today or tomorrow" and Rubio cited progress. The broader nuclear and regional-security file is untouched. Al Jazeera

Mets take the second one in Cleveland, 6–2. Luis Torrens 3-for-3 with a homer and four RBI. Nolan McLean (7–7, 3.29) goes tonight against Tanner Bibee. Jefferson Rojas — the Cubs' No. 2 prospect who came back in the Holmes/Taylor deal — is now the organization's No. 1 and a September call-up candidate. Baseball America

Watchable: Ted Lasso S4 is out on Apple TV with mixed-to-warm first reviews, and Prime Video's August adds include several titles at 90%+ on Rotten Tomatoes. Nolan's The Odyssey is still the one worth the theater. Tom's Guide

Golf tech: no new releases in the past 48 hours — seventh straight quiet day. The year's live options remain Shot Scope's LM1 at $200, Square's four-camera Omni, and Garmin's G82. The action has moved to software; Uneekor's AI swing analysis is where people are pointing. The Golf Wire

D · Trends to Watch

FDA approval and patient access have formally decoupled. mFlusiva is licensed and unavailable in any practical sense to the population it most matters for, because the committee that unlocks coverage can't legally vote. Expect this pattern to repeat for every product approved while ACIP is in limbo — the regulatory question is settled and the reimbursement question is orphaned.

Two live produce outbreaks, both tracing to Mexican imports. Iceberg lettuce from central Mexico, jalapeños from Sinaloa. Detection worked in both; traceback speed is what separated them — Salmonella got a named distributor in weeks, Cyclospora has no whole-genome sequencing and is still on multiple unresolved clusters months in.

National case counts are becoming a lagging, single-state-weighted signal. CDC is now carrying more unconfirmed cyclosporiasis cases (12,255) than confirmed ones (10,468), most of the unconfirmed from one state, on a six-week reporting lag. The number you read is a description of early July.

AI adoption in hospital medicine has outrun training. Roughly two-thirds of hospitalists are using it, and two-thirds of those say they were never adequately trained on it. That gap — competent tool, untrained user, unclear documentation standard — is where the liability problems will surface first, and nobody is measuring it yet.

E · Ideas & Opportunities

Get the mFlusiva formulary answer in August. One email to pharmacy and infection prevention: will we stock it, and what does the discharge flu order do with an FDA-approved vaccine that has no ACIP recommendation? This becomes an every-shift friction point in October if nobody decides it now.

Update the summer diarrheal history line. Keep the fast-casual Mexican question, but split it: jalapeño exposure is a closed June 14–July 14 window; lettuce is still open. And confirm with the lab whether your multiplex GI panel reports Cyclospora or whether it needs a separate modified acid-fast request — that's the step that gets missed.

Post-shift queue: Ted Lasso S4 if you want something undemanding; The Odyssey if you'd rather leave the house.